There is enhanced clinical pharmacological effect by combining tRES with HESP on glycemic control and insulin resistance, likely through synergism in activation of Nrf2 and HESP improving the bioavailability of tRES [202,215]. The gene discussed is NFE2L2; the disease is Insulin resistance.